NEW YORK--Zeneca Pharmaceuticals' Casodex, an oral antiandrogen agent, has received approval for marketing in the United Kingdom for the treatment of advanced prostate cancer. Zeneca has also filed for approval of Casodex in the United States and several other countries, Zeneca president Robert C. Black said at a media briefing.
Other new anticancer agents from Zeneca in clinical development include Tomudex, a cytotoxic thymidylate synthase inhibitor for colorectal cancer, and Arimidex, an oral nonsteroidal aromatase inhibitor for breast cancer.
The company's LHRH agonist analog Zoladex (goserelin acetate), currently marketed as a 3.6 mg implant for prostate cancer, has been recommended for a new indication--palliation of advanced breast cancer . An NDA has also been filed for a 10.8-mg, 3-month depo formulation, Mr. Black said.